Figure 2 -

Eupraxia Pharmaceuticals Inc.

Mean change in EoEHSS from baseline at 4, 12 and 36 weeks for Cohorts 5-8 in the Phase 1b/2a portion of the RESOLVE trial.

Format

JPEG

Quelle:

Eupraxia Pharmaceuticals Inc.

Downloads